Alyra Biotech Pty Ltd Biopharmaceutical Company

Alyra Biotech Pty Ltd is a privately-owned, biopharmaceutical company that develops products for intrauterine delivery that target neuroimmune mechanisms in the pelvis, spinal cord and circulation, including pain.
Alyra Biotech has developed a broad technology, patented, platform of devices focused both on high-value targets and on products suited to use in low resource settings throughout the world. Our products seek to deliver safer, effective, low dose treatments for women with pain, pain-related or menstrual cycle-related symptoms.
The target medical conditions include those involving excess activation of the immune system within the uterus, bladder or bowel of women. These conditions include pelvic pain, dysmenorrhea, endometriosis-related pain, irritable bowel syndrome, painful bladder syndrome, migraine, fatigue, and premenstrual syndrome.
Current systemic treatments to reduce immune activation are available. However, systemic side effects when used orally limit their use. By re-purposing drugs with known human safety data, and targeting local delivery to the uterus, our products offer a low dose option with low side effect profile.
Our in-house preclinical proof-of-concept research has been replicated and extended to endometriosis by Bashir et al. at the University of Illinois (2023)
A US patent for our first patent family was granted in 2022. An additional patent family will extend our reach to additional clinical indications.

Building on 20 years of multi-disciplinary clinical and research experience, Gynecologist and Pain Physician, Dr Susan Evans, founded Alyra Biotech in 2017 to address the need for novel products to treat pelvic pain in women. Pelvic pain affects between 15% and 25% of women in our community and is a large area of global unmet human need.
Following the success of in-house preclinical research, the potential application of Alyra Biotech's technology to a wide range of medical conditions was realized.
Throughout this process, it is the needs and wishes of women that have guided Alyra Biotech's philosophy. We are in close association with women's groups and the Pelvic Pain Foundation of Australia. Our team considers the priorities identified by women themselves, considers the needs of clinicians, utilizes clinical expertise, undertakes laboratory-based scientific research, provides novel options and consults with women regarding the suitability of our discoveries.
We recognize that young women expect effective treatments for their pelvic pain or menstrual cycle-related symptoms that are effective and easy-to-use, with few adverse effects and minimal interruption to their natural hormonal cycle.

The prevention of immune system activation in young women offers a ‘Holy Grail’ opportunity for the prevention of female chronic pain.
Our products offer a new life trajectory for young women with pain, by reducing immune activation and preventing the transition from dysmenorrhea to chronic pelvic pain.
Glial activation in the central nervous system has been associated with a wide range of symptoms and conditions. For this reason, our products have potential benefits for a wide range of additional medical conditions that involve sex-specific inflammatory mechanisms.
Alyra Biotech is a recipient of a Clinical Phase CUREator Grant funded by Australia's Medical Research Future Fund following an extensive due diligence process.
Ethics Approval for first-in-human trials has been granted and will commence in 2023

For further information on our biopharmaceutical company Alyra Biotech,
contact the CEO Dr Susan Evans

Parker MA, Sneddon AE, Arbon P. The Menstrual disorder of teenagers (MDOT) study: determining typical menstrual patterns and menstrual disturbance in a large population-based study of Australian teenagers. BJOG. 2010 Jan;117(2):185-92.
Bashir et al. Endometriosis leads to central nervous system-wide glial activation in a mouse model of endometriosis. J Neuroinflammation. 2023.

About Alyra Biotech Pty Ltd